The Clinical Services segment focuses on providing a wide range of oncology diagnostic and prognostic testing services to hospitals, pathologists, oncologists, and other healthcare providers. This includes cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, and molecular testing. Research and development efforts are directed towards expanding the test menu, improving assay sensitivity and specificity, and incorporating new technologies such as next-generation sequencing (NGS). The segment aims to improve patient outcomes by providing accurate and timely diagnostic information that guides treatment decisions. Key areas of focus include hematologic malignancies, solid tumors, and inherited genetic disorders. The segment also emphasizes personalized medicine approaches, leveraging genomic data to tailor treatment strategies to individual patients. Future opportunities include expanding into new geographic markets and developing companion diagnostics for targeted therapies.

The Pharma Services segment supports pharmaceutical companies in their oncology drug development programs, from discovery to commercialization. This includes providing testing services for clinical trials, biomarker discovery, and companion diagnostic development. Research and development activities are focused on identifying and validating novel biomarkers, developing assays for drug response prediction, and providing comprehensive genomic profiling services. The segment utilizes a variety of technologies, including NGS, immunohistochemistry, and flow cytometry, to support drug development efforts. The goal is to accelerate the development of new cancer therapies and improve patient outcomes by identifying patients who are most likely to respond to specific treatments. Key areas of focus include immuno-oncology, targeted therapies, and personalized medicine. Future opportunities include expanding into new therapeutic areas and developing innovative diagnostic solutions for drug development.